GlassScriptPhysician profile
Amy M Eversole
NPI 1760442560
$6,637.10
in general payments reported to CMS, 2019-2025
37 companies · $813 in 2025
The $813 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $472 · 2021: $1,006 · 2022: $1,191 · 2023: $922 · 2024: $1,500 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,235.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,301.36 | 2019-2024 | Xarelto |
| Pfizer INC. | $723.04 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $583.14 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $407.18 | 2021-2024 | Amplatzer Amulet |
| Novartis Pharmaceuticals Corporation | $375.45 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $368.91 | 2022-2025 | Verquvo, Winrevair |
| Medtronic, INC. | $360.59 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.25 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $263.86 | 2019-2025 | Farxiga |
| United Therapeutics Corporation | $227.71 | 2024-2025 | Tyvaso, Tyvaso |
| Sanofi-Aventis U.S. LLC | $211.17 | 2019-2024 | |
| Amgen INC. | $201.33 | 2019-2024 | Repatha |
| Atricure, INC. | $171.11 | 2024 | |
| Boston Scientific Corporation | $142.46 | 2023-2025 | Watchman Flx |
| Kestra Medical Technology Services, INC. | $140.12 | 2024-2025 | Assure Wcd |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Eversole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.